作者：
Lucas Hendrik,Overeem [1]
;
Bianca,Raffaelli [2]
;
Robert,Fleischmann [1]
;
Marie,Süße [3]
;
Antje,Vogelgesang [4]
;
Aleksandra Maleska,Maceski [4]
;
Athina,Papadopoulou [4]
;
Klemens,Ruprecht [5]
;
Wendy,Su [6]
;
Mirja,Koch [5]
;
Anke,Siebert [6]
;
Michal,Arkuszewski [1]
;
Nadia,Tenenbaum [7]
;
Jens,Kuhle [7]
;
Uwe,Reuter [1]
作者单位：
Department of Neurology With Experimental Neurology, Charité - Universitätsmedizin Berlin, Charitéplatz 1, Berlin, 10117, Germany.
[1]
Doctoral Program, International Graduate Program Medical Neurosciences, Humboldt Graduate School, Berlin, 10117, Germany.
[2]
Clinician Scientist Program, Berlin Institute of Health (BIH), Berlin, 10117, Germany.
[3]
Department of Neurology, Universitätsmedizin Greifswald, Greifswald, 17475, Germany.
[4]
Department of Neurology, University Hospital and University of Basel, Basel, 4051, Switzerland.
[5]
Multiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, 4051, Switzerland.
[6]
Novartis Pharma AG, Basel, 4056, Switzerland.
[7]
EMD Serono Research and Development Institute, New York, NY, USA.
[8]
Department of Neurology With Experimental Neurology, Charité - Universitätsmedizin Berlin, Charitéplatz 1, Berlin, 10117, Germany. uwe.reuter@charite.de.
[9]
Department of Neurology, Universitätsmedizin Greifswald, Greifswald, 17475, Germany. uwe.reuter@charite.de.
[10]
DOI
10.1186/s10194-023-01663-5
PMID
37726712
发布时间
2023-11-21
换一批
换一批
